All HER2-Positive Tumors are not Created Equal

Elizabeth A Mittendorf¹, Mariana Chavez-MacGregor^{2

3}

Affiliations

¹ Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. eamitten@mdanderson.org.
² Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Editorial

Elizabeth A Mittendorf et al. Ann Surg Oncol. 2017 Nov.

. 2017 Nov;24(12):3471-3474.

doi: 10.1245/s10434-017-6053-6. Epub 2017 Aug 16.

Elizabeth A Mittendorf¹, Mariana Chavez-MacGregor^{2

3}

¹ Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. eamitten@mdanderson.org.
² Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Comment on

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Beitsch P, Whitworth P, Baron P, Rotkis MC, Mislowsky AM, Richards PD, Murray MK, Pellicane JV, Dul CL, Nash CH, Stork-Sloots L, de Snoo F, Untch S, Lee LA. Beitsch P, et al. Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. Epub 2017 Apr 26. Ann Surg Oncol. 2017. PMID: 28447218 Clinical Trial.